

Take Home Messages

MDS & AML

Rami Komrokji, MD

Senior member and Professor of Oncologic Sciences

Vice chair, Malignant Hematology Department

Moffitt Cancer Center

Tampa, Florida

MDS

- New classification systems ICC/WHO 2022.
- IPSS-M a new risk stratification model.
- Lower risk MDS
 - Early use of lenalidomide in del5q MDS
 - Luspatercept
 - Imetelstat
- Higher risk MDS
 - On going p3 clinical trials combinations.
 - Oral hypomethylating agents.
 - HMA failure treatment.

AML

- New classification systems ICC/ELN 2022.
- ELN risk stratification refined.
- Evolving role for MRD assessment in management.
- Non-intensive approach/targeted therapy
 - Longer follow up on HMA/Ven trials
 - Triplet combinations in FLT-3 MT AML
 - Triplet combination in TP 53 MT AML.
 - IDH-1/IDH-2 inhibitors role.
 - Menin inhibitors in clinical trial.
- Intensive approach:
 - When to use intensive chemotherapy.
 - Questioning the role of pre-transplant treatment in relapsed AML.